By Christine Chen (Reuters) -Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were ...

ASIC released their latest insolvency statistics earlier this week and the results are concerning. A company becomes ...

Australian consumer sentiment remained in the doldrums in February, a survey showed on Tuesday, failing to benefit from ...

A historic cut to living standards has occurred, mostly since Labor scraped into office in May 2022, fuelling a political ...

Add articles to your saved list and come back to them any time. Australian super funds’ expenses swelled to almost $13 billion last financial year, including a $500 million splurge on an ...

The second release of fund-level expenditure data by the Australian Prudential Regulatory Authority shows total industry expenditure was up by 15 per cent for the 2024 financial year ending June 30.